Headquartered in Paris and London, Óskare Capital specializes in venture-stage investments in the Deeptech and Life Sciences sectors
Current Portfolio
Octarine have developed a leading synthetic biology platform, disrupting the sustainable bio-based dyes market in the process.
Country
Denmark
First Investment
2019
Company
Octarine Bio
Invested At
Pre-Seed
Herbolea develops and licenses and operates proprietary, solvent-less technologies to transform botanicals into superior quality products.
Country
Italy / USA
First Investment
2020
Company
Herbolea
Invested At
Seed
Leva is a leading UK chronic pain digital clinic, providing alternatives to opiates and helping solve the opioid addiction epidemic.
Country
UK
First Investment
2021
Company
Leva
Invested At
Seed
Prohibition Partners hold renowned European conferences and is a leading data provider.
Country
UK
First Investment
2022
Company
Prohibition Partners
Invested At
Series A
Aelis Farma is a clinical biopharmaceutical company specialising in the development of treatments for brain diseases including addiction (cannabis) and improving the quality of life of people with Down’s Syndrome by helping restore functional memory.
Country
France
First Investment
2022
Company
Aelis Farma
Invested At
Post-IPO
Get In Touch
For more information on how to invest in Oskare Fund I or on our portfolio companies, feel free to contact us